Chemotherapy Options for Heavily Pre-Treated Recurrent Triple-Negative Breast Cancer

Introduction to Treatment Options

The American Society of Clinical Oncology recommends sacituzumab govitecan as the strongest evidence-based option for patients with triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease, with a dramatic superiority showing 35% vs 5% objective response rate compared to chemotherapy 1, 2

Germline BRCA1/2 mutation testing is essential, and if positive, PARP inhibitors (olaparib or talazoparib) are strongly preferred over chemotherapy, with 40-60% improvement in progression-free survival, as recommended by the National Comprehensive Cancer Network 3, 2, 4
PD-L1 testing is also crucial, and if PD-L1 positive (≥1% tumor-infiltrating immune cells), immunotherapy combinations may still be considered, according to the National Comprehensive Cancer Network 2, 4

For patients who have received ≥2 prior lines for metastatic disease, sacituzumab govitecan is the category 1 preferred option, demonstrating an objective response rate of 35% vs 5% with chemotherapy, and a median PFS of 5.6 vs 1.7 months (HR 0.41), as recommended by the American Society of Clinical Oncology 2, 4
If BRCA1/2 mutation positive, PARP inhibitors (olaparib or talazoparib) are strongly preferred over chemotherapy, showing doubled response rates compared to standard therapy, and a median PFS improvement from 4.2 to 7.0 months (HR 0.58), according to the National Comprehensive Cancer Network 3, 2

Eribulin is the preferred chemotherapy option for heavily pre-treated TNBC, demonstrating a 19% risk reduction in death (HR 0.81, p=0.041), and a median OS of 13.1 vs 10.6 months compared to physician's choice, as recommended by the National Comprehensive Cancer Network 6
Alternative single-agent options include gemcitabine, vinorelbine, and ixabepilone, which have shown activity in heavily pre-treated patients, although likely less effective than eribulin, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 5, 3, 6

Platinum rechallenge should be avoided due to increased toxicity without clear benefit, as recommended by the National Comprehensive Cancer Network 3, 1
Combination chemotherapy should not be used, as it yields higher response rates but does not improve overall survival and significantly increases toxicity, according to the European Society for Medical Oncology and the American Society of Clinical Oncology 5, 1
Clinical trial enrollment should be strongly considered for patients with limited remaining standard options, as recommended by the European Society for Medical Oncology 5

If using eribulin, monitor for peripheral neuropathy (14% grade 3/4) and neutropenia (54% grade 3/4), as recommended by the National Comprehensive Cancer Network 6
If using sacituzumab govitecan, monitor for neutropenia, diarrhea, and nausea as primary toxicities, according to the American Society of Clinical Oncology 1
If using PARP inhibitors, monitor for anemia, nausea, and fatigue, and ensure cardiac monitoring if prior anthracycline exposure was significant, as recommended by the National Comprehensive Cancer Network 3